EUVIMEDEUVIMED entdecken
Open Access

Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery

Nobuki Furubayashi, Takehito Kojima, Yasuhiro Nakano, Akari Kataoka, Motonobu Nakamura, Takahito Negishi

In Vivo · 2026-07 · 40 (4) · 2280-2288

DOI: 10.21873/invivo.14380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, online erschienen am 30.06.2026. Verfasst von Nobuki Furubayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan furubayashi.nobuki.yc@mail.hosp.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Renal CellKidney NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMaleAgedMiddle AgedChemotherapy, AdjuvantRetrospective StudiesAged, 80 and overTreatment OutcomeAdult

Stichwörter der Autor:innen

Renal cell carcinomaadjuvant pembrolizumabclear cell renal cell carcinomadisease-free survivalreal-world studysafety

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan furubayashi.nobuki.yc@mail.hosp.go.jp.
  • Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.

Zitieren

APA

Furubayashi, N., Kojima, T., Nakano, Y., Kataoka, A., Nakamura, M., & Negishi, T. (2026). Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In Vivo, 40(4), 2280-2288. https://doi.org/10.21873/invivo.14380

Vancouver

Furubayashi N, Kojima T, Nakano Y, Kataoka A, Nakamura M, Negishi T. Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In Vivo. 2026;40(4):2280-2288. doi:10.21873/invivo.14380

BibTeX
@article{Furubayashi2026,
  author = {Furubayashi, Nobuki and Kojima, Takehito and Nakano, Yasuhiro and Kataoka, Akari and Nakamura, Motonobu and Negishi, Takahito},
  title = {Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {2280--2288},
  doi = {10.21873/invivo.14380}
}
Kostenlos starten →